The usage of CEA, Cyfra21‐1, and NSE tests was similar within 3 months before first discharge with diagnosed different subtypes of NSCLC, and all utilization rates were approximately 60% (Figure 3). The gene discussed is ENO2; the disease is non-small cell lung carcinoma.